Appointment

RNS Number:7718J
GW Pharmaceuticals PLC
11 September 2001


For immediate release                                         11 September 2001



                            GW Pharmaceuticals plc

                            ("GW or "the Company")

                       Appointment of Finance Director



GW is pleased to announce the appointment of David Kirk as Finance Director,
with immediate effect. Mr Kirk succeeds Jonathan Laughton who steps down from
the Board but will continue in his role of Company Secretary and becomes
Financial Controller.

David Kirk (age 47) joined Arthur Andersen in 1975, qualifying as a Chartered
Accountant in 1978 and becoming a partner in 1988. At Arthur Andersen he
specialised in entrepreneurial growth companies and worked across a range of
sectors. He was responsible for launching the UK Arthur Andersen Biotech
Programme in 1994 whilst Head of its UK Technology Team.

In early 1997 he became the first Finance Director of CeNeS Limited, the
company developing drugs for CNS disorders and pain control, playing a
significant role in its development, including its reverse into Core Group PLC
(which subsequently became CeNeS Pharmaceuticals Plc). He left CeNeS in summer
2000. He was also a founding Director of Amura Limited, an antibacterial
research company, and was until June 2001 a non executive Director of Avlar
Bioventures, a biotechnology venture capital fund based in Cambridge.

Dr Geoffrey Guy, Executive Chairman, commented: "David is well known to GW and
has already worked with the Company in a consultancy capacity. I am delighted
to welcome him to the Board. His extensive financial and healthcare experience
will be of great benefit to the Company as we expand our late stage clinical
programme and scale up operations ahead of market launch."

"As Finance Director, Jonathan has played a vital role in the early years of
GW's life and we look forward to his continuing contribution to the Company's
development."

David Kirk, commented: "Over recent months, I have come to know GW well and am
very excited by the Company's prospects. I look forward to working with the GW
board and management team at this very important time in the Company's
development."

A list of David Kirk's current and former directorships is attached as an
appendix to this announcement.


Enquiries:
GW Pharmaceuticals plc                                 (11/09/01) 020 7601 1000
Dr Geoffrey Guy, Executive Chairman                  (Thereafter) 01980 619 000
Justin Gover, Managing Director
David Kirk, Finance Director

Square Mile BSMG Worldwide                                        020 7601 1000
Kevin Smith/Graham Herring

Website: www.gwpharm.com


Appendix
DAVID FRANCIS KIRK - LIST OF CURRENT AND FORMER DIRECTORSHIPS & PARTNERSHIPS

Former directorships or partnerships held since 1 September 1996:

CENES PHARMACEUTICALS PLC
CENES DRUG DELIVERY LIMITED
CENES RESEARCH LIMITED
CENES LIMITED
CENES CONTRACT RESEARCH LIMITED
EQUADOR PLC
EQUADOR CONSULTING LIMITED
EQUADOR GROUP SERVICES LIMITED
AMURA LIMITED
AVLAR BIOVENTURES LIMITED
QUANTUM HEALTHCARE FUND (CARRIED INTEREST PARTNER) LTD
QUANTUM HEALTHCARE FUND (GENERAL PARTNER) LIMITED
ACLAR LIMITED
PINCO 830 LIMITED - DISSOLVED JUNE 1998
THE LEO BAECK COLLEGE
DKASSOCIATES

Current directorships:

PINCO 1182 LIMITED

There are no further disclosures to be made in respect of David Kirk pursuant
to paragraph (f) of Schedule 2 of the AiM Rules for companies.